Capricor posts widening losses, $122.8M cash runway as FDA CRL and HOPE-3 topline loom

Capricor Therapeutics, Inc. (NASDAQ: CAPR) - Quick internal update & income-statement highlights

What's happening inside
* BLA & regulatory: Company completed rolling BLA (Dec 2024); FDA accepted and granted Priority Review. In May 2025 FDA performed PLI and issued Form 483 observations that Capricor says it has addressed. In July 2025 Capricor received a Complete Response Letter (CRL) requesting additional clinical evidence and citing some CMC items; Capricor is preparing a formal CRL response and scheduled a Type A meeting with FDA (Aug 2025).
* Clinical: HOPE‑3 Phase 3 completed 12‑month treatment; topline expected Q4 2025 (study remains blinded). HOPE‑2 OLE reporting positive 4‑year signals. Company shifted HOPE‑3 primary endpoint to LVEF (cardiac focus).
* Commercial partnerships: Ongoing distribution partnerships with Nippon Shinyaku (U.S., Japan; binding term sheet for Europe) with multiple milestone and sales‑share upside. Nippon provided prior upfront/milestone payments that materially funded R&D and operations.
* Manufacturing & buildout: Capital investment and expansion underway - property & equipment up and construction in progress recorded; lease amendments (San Diego expansion) will add substantial future lease liabilities (~$13.5M ROU/lease liabilities expected in Q3 2025 per filing).
* Legal & governance: Post‑period putative securities class action (filed July 17, 2025) and a derivative action (Aug 1, 2025). No material accruals recorded as of June 30, 2025.

Key balance sheet & cash facts (exact figures)
* Cash and cash equivalents: $23,241,199 (June 30, 2025)
* Marketable securities: $99,559,482 (June 30, 2025)
* Cash + marketable securities: approximately $122.8 million (June 30, 2025, reported)
* Total assets: $133,569,011 (June 30, 2025)
* Total liabilities: $28,591,955 (June 30, 2025)
* Stockholders' equity: $104,977,056 (June 30, 2025)
* Working capital: $95,729,000 (reported table, June 30, 2025)
* CIRM liability (current): $3,376,259 (June 30, 2025) - Capricor elected to convert the grant to a loan (accrued interest could reach ~ $7.1M depending on terms)

Income statement - key numbers (as reported)
* Revenue: $0 for three months ended June 30, 2025 (Q2 2025); Revenue was $3,971,438 in Q2 2024. Six months ended June 30, 2025 revenue $0 vs $8,878,315 in 2024.
* Total operating expenses: $27,719,134 (Q2 2025) vs $15,562,657 (Q2 2024). Six months: $52,702,082 (2025) vs $30,735,436 (2024).
* R&D expense: $22,047,254 (Q2 2025) vs $12,504,769 (Q2 2024). Six months: $40,962,826 (2025) vs $23,605,782 (2024).
* G&A expense: $5,671,880 (Q2 2025) vs $3,057,888 (Q2 2024). Six months: $11,739,256 (2025) vs $7,129,654 (2024).
* Other / investment income: $1,808,343 (Q2 2025 other income, incl. investment income ~$1.79M) - investment income helped offset part of expenses.
* Net loss: $(25,910,791) (Q2 2025) vs $(10,999,782) (Q2 2024). Six months net loss $(50,302,385) (2025) vs $(20,793,855) (2024).
* Net loss per share, basic & diluted: $(0.57) Q2 2025 vs $(0.35) Q2 2024. Weighted average shares: 45,709,071 (Q2 2025) vs 31,841,964 (Q2 2024).

Positive aspects of the income statement / finances
* Strong liquidity buffer: ~$122.8M in cash + marketable securities gives runway (company estimates funding into Q4 2026).
* Partnership cash support: Nippon Shinyaku upfront and milestone payments materially funded 2022-2024 activity (and $10M milestone received Jan 2025).
* Investment income rising: Investment income increased (YTD ~$2.5M) helping offset cash burn.
* Strategic spend: Elevated R&D and G&A reflect preparation for potential commercialization (CMC, manufacturing scale‑up, HOPE‑3), an investment profile investors expect in late‑stage biotech.

Negative aspects of the income statement / risks
* Revenue disappearance: Revenue fell to $0 in reporting periods (no product sales; milestone recognition timing produced prior revenue but not in Q2 2025).
* Sharp expense growth and cash burn: Total operating expenses up materially (R&D +74% YoY for six months); net loss widened to $50.3M YTD - cash used in operations $26.6M for six months.
* Dependence on financing / milestones: Continued development and commercialization still require substantial funding; further dilution or financing risk exists.
* Regulatory setback: CRL (July 2025) materially raises the prospect of additional trial or confirmatory data, delaying or altering approval path and potential near‑term revenue.
* Contingent liabilities: CIRM loan conversion could add accrued interest (up to ~$7.1M possible) and lease amendments will add large future lease liabilities (~$13.5M added in Q3 2025 estimate). Legal actions filed post‑period introduce litigation cost risk.

Bottom line - in one paragraph
Capricor (NASDAQ: CAPR) is deploying significant capital into late‑stage development, manufacturing scale‑up and commercialization prep for deramiocel. The balance sheet is solid for now (~$122.8M of cash + securities; runway guidance into Q4 2026), but operating losses have accelerated (YTD net loss $50.3M) and the July 2025 CRL plus recent litigation increase uncertainty and likely require more spend and time to resolve regulatory and legal issues. The company's near‑term valuation sensitivity will depend on HOPE‑3 topline, the CRL response/FDA guidance and any additional financing or partnership activity.

Sources: Capricor Therapeutics, Inc. Form 10‑Q for the quarter ended June 30, 2025 (filed Aug 11, 2025) - condensed financial statements and MD&A.